Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03555851 · ClinicalTrials.gov registry record
Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy
A clinical trial of Leukemia, Other and Leukemia, Not Otherwise Specified, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT03555851: Recruiting study of Leukemia, Other and Leukemia, Not Otherwise Specified, sponsored by Wake Forest University Health Sciences.
NCT03555851 is a study of Leukemia, Other and Leukemia, Not Otherwise Specified that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 120 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03555851, a study of Leukemia, Other and Leukemia, Not Otherwise Specified, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the influence of donor and recipient pharmacogenetics (PG), drug pharmacokinetics (PK), and T cell phenotypes and how it may permit a tailored dosing strategy to improve the therapeutic index of post-transplant cyclophosphamide (PTCy) and optimize the graft versus tumor effect, while minimizing acute and chronic graft versus host disease (GVHD).
Primary Outcome
Evaluation and comparison of average Day 3 Cy cMax values between subjects who experience acute GVHD versus subjects who do not experience acute GVHD
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- OTHER Specimen collection
Study Locations (1)
North Carolina
- Levine Cancer Institute - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2018-07-13 |
| Est. Completion | 2035-08 |
What NCT03555851 shows while recruiting
NCT03555851 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 2 conditions, with Leukemia, Other appearing as the primary indexed condition, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT03555851 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03555851 about?
NCT03555851 is a clinical study titled "Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy". This study will examine the influence of donor and recipient pharmacogenetics (PG), drug pharmacokinetics (PK), and T cell phenotypes and how it may permit a tailored dosing strategy to improve the therapeutic index of post-transplant cyclophosphamide (PTCy) and optimize the graft versus tumor effec...
What is the current status of trial NCT03555851?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2018-07-13. Estimated completion is 2035-08.
What conditions does trial NCT03555851 study?
This clinical trial studies the following conditions: Leukemia, Other, Leukemia, Not Otherwise Specified.
What interventions are being tested in trial NCT03555851?
The interventions under investigation include: Cyclophosphamide (DRUG), Specimen collection (OTHER).
Who is sponsoring clinical trial NCT03555851?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03555851 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Other
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI